Equities

Metagenomi Inc

MGX:NSQ

Metagenomi Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.21
  • Today's Change0.12 / 5.74%
  • Shares traded631.96k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments271362108
Total Receivables, Net2.451.950.49
Total Inventory------
Prepaid expenses4.642.820.27
Other current assets, total------
Total current assets278367109
Property, plant & equipment, net653322
Goodwill, net------
Intangibles, net------
Long term investments117.816.42
Note receivable - long term------
Other long term assets0.370.450.53
Total assets365414142
LIABILITIES
Accounts payable1.792.011.35
Accrued expenses15104.22
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total523620
Total current liabilities694925
Total long term debt0030
Total debt0030
Deferred income tax------
Minority interest------
Other liabilities, total819443
Total liabilities15014398
SHAREHOLDERS EQUITY
Common stock0.030.030.03
Additional paid-in capital------
Retained earnings (accumulated deficit)(136)(74)(33)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.1)(0.27)(0.02)
Total equity21527244
Total liabilities & shareholders' equity365414142
Total common shares outstanding383838
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.